INmune Bio and QCi Apply Quantum Computing to XPro Research
Oct 14, 2026
Life Sciences
Cantex and Headlamp Partner to Advance Azeliragon for MS Depression and Fatigue
May 14, 2026
Cantex Pharmaceuticals and Headlamp Health have announced a partnership to use Headlamp's Lumos AI platform to accelerate the development of azeliragon for treating severe depression and fatigue in multiple sclerosis patients.
Cantex Pharmaceuticals and Headlamp Health announced in a press release a collaboration to apply Headlamp's Lumos AI platform to the clinical development of azeliragon for severe depression and fatigue in patients with multiple sclerosis.
Headlamp's Lumos AI is a neuro symbolic, multi agent platform designed for neuropsychiatric drug development. It integrates biological, behavioral, biomarker, and clinical data into a unified intelligence layer, helping teams identify responder and non responder subtypes earlier and refine trial design.
Under the agreement, Headlamp Health will deploy Lumos AI to analyze data across azeliragon's development program. Azeliragon is an oral, blood brain barrier penetrant RAGE inhibitor in clinical development, targeting neuroinflammatory processes linked to depression and fatigue in multiple sclerosis patients.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Enterprise
Oct 16 McGraw Hill Adds AI Study Tools to Connect Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 ALTOUR Unveils AI Platform for Corporate Travel Decisions Oct 16 BOC Group Adds AI Assistant to ADOIT 21More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Quotient Sciences and Acesion Apply AI to Atrial Fibrillation Drugs
Oct 05, 2026
Biotech
XtalPi Advances Hair Loss Drug Into IND Enabling Studies
Oct 05, 2026
Biotech
Linearis Joins Two Canadian AI Health Data Projects
Sep 16, 2026
Healthcare
Sensydia Raises More Than $6 Million for AI Cardiac System
Oct 13, 2026
Funding
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.